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1056Objectives:Allograft vascular tissue is important in the repair of complex structural lesions of the heart and great
vessels, but induces a deleterious immune response that might shorten the effective lifespan of the tissue and
sensitize the recipient. We hypothesized that decellularizing allograft vascular tissue reduces the host allogeneic
immune response.
Methods: Allograft ovine pulmonary artery patches were decellularized, cryopreserved, and implanted into the
descending thoracic aorta. The humoral immune response was measured by means of flow cytometry at regular
intervals over 6 months. Graft histology, immunohistochemistry, and calcification were assessed after 4 weeks or
6 months.
Results: Leukocyte infiltration was reduced in decellularized grafts. A trend toward decreased in-patch calcifi-
cation was observed in the decellularized group (7.6  4.3 vs 40.0  15.9 mg of calcium/mg of protein,
P ¼ .107). Decellularization reduced IgG antibody binding to donor splenocytes (9.8%  3.3% vs 57.8% 
13.7% [control value], P¼ .010), as assessed by means of flow cytometry. All cytokines examined were detected
in nondecellularized tissues after 4 weeks but not at 6 months, indicating complete graft rejection at that time. In
contrast, transforming growth factor b1 and interleukin 10 were the only prominent cytokines in all decellularized
grafts at 4 weeks after transplantation.
Conclusions:Decellularization of allograft vascular tissue minimized the recipient cellular immune response and
eliminated the production of anti-donor antibodies in recipients. (J Thorac Cardiovasc Surg 2011;141:1056-62)Allograft cardiovascular tissue has been used to reconstruct
congenital and acquired lesions of the heart and great vessels
in pediatric and adult populations since the 1950s. Cryopre-
served allograft vascular tissue has superior handling charac-
teristics, provides an excellent hemodynamic profile, and
does not require anticoagulation, but elicits a strong cellular
and humoral1-3 immune response in recipients. Allograft
valve conduits incite the development of anti–human
leukocyte antigen class I and II antibodies4 that remain de-
tectable after 8 years.5 Although the significance of this hu-
moral immune response is debated,6 it might accelerate the
deterioration of the allograft, resulting in structural valve
failure7,8 and reduced freedom from reoperation9 and might
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The Journal of Thoracic and Cardiovascular Surimmune response is more profound in younger age groups
and might accelerate the destruction of the allograft in this
population.
Cellular elements in the graft might be primarily respon-
sible for the allogeneic immune response. An attractive strat-
egy is to target the conduit. Decellularizing the allograft
might attenuate the host’s immune response12 by eliminat-
ing major histocompatibility complex antigens on the con-
duit. No studies to date have measured the development of
anti-donor antibody in a large-animal model. We intended
to assess the long-term effect of graft decellularization on
cellular and humoral immune responses in sheep.MATERIALS AND METHODS
Approval for this study was obtained from the University of Alberta
Animal Care and Use Committee. The funding organizations assumed no
role in data collection, analysis, interpretation, or the right to approve or
disapprove publication of the final manuscript.
Experimental Animals
Suffolk sheep were purchased from a local farm and housed at the Uni-
versity of Alberta farm in accordance with the guidelines of the Canadian
Council on Animal Care.13 They were provided standard food and water
ad libitum. Mixed lymphocyte reaction assays were performed, as previ-
ously described, to ensure allogenicity between donor and recipient pairs.14
Donor Patch Procurement and Preparation
After achievement of general halothane anesthesia, by using aseptic
techniques, a large trapdoor incision was made over the left hemithorax,gery c April 2011
Abbreviations and Acronyms
FACS ¼ fluorescence-activated cell sorting
IFNG ¼ interferon
IL ¼ interleukin
RT–PCR ¼ reverse transcription–polymerase
chain reaction
TGFB ¼ transforming growth factor b
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Sand the animal was exsanguinated. Donor pulmonary arteries were immedi-
ately procured in a manner similar to the Ross procedure and transported in-
RPMI culture media (Gibco, Grand Island, NY). Donor tissue was
decellularized in a series of hypotonic and hypertonic tris(hydroxymethyl)a-
minomethane (tris) buffers with 0.5% polyethylene glycol p-(1,1,3,
3-tetramethylbutyl)-phenyl ether (Triton X-100; Labchem, Inc, Pittsburgh,
Pa) as a detergent, as previously described.15 Control tissues were prepared
similarly but were not decellularized before cryopreservation.
Cryopreservation
Following the protocol of our tissue bank, decellularized and control tis-
sues were sterilized in antibiotic solution (colistimethate [Sterimax, Inc,
Mississauga, Ontario, Canada], vancomycin hydrochloride [Pharmas-
cience, Inc, Montreal, Quebec, Canada], lincomycin [Pharmacia, Kirkland,
Quebec, Canada], and cefoxitin sodium [Novopharm, Toronto, Ontario,
Canada]) for 24 hours. Valve conduits were rinsed and transferred into
7.5% Me2SO (Fisher Scientific, Fair Lawn, NJ) in X-Vivo (Cambrex Bio
Science, Walkersville, Md), packaged, and frozen over 5 phases (Cryomed
1010; Cryomed, Mount Clements, Mich). Tissues were cooled from ambi-
ent temperature to 4C, supercooled to2C, and seeded by applying a burst
of vapor-phase nitrogen to initiate ice formation in the supercooled sample.
Cooling proceeded at 1C/min to 50C and then at 7C/min until the
allograft reached 100C. Conduits were stored in vapor-phase liquid
nitrogen.
Implant Procedure
Donor tissue was thawed, and a 2 3 4–cm diamond-shaped patch was
cut from the main pulmonary artery and implanted in the descending
thoracic aorta, as previously described.16 In short, recipient animals were
anesthetized with halothane and nitrous oxide. After oral–tracheal intuba-
tion, ampicillin (1 g, Novopharm), gentamicin (1 g; Sandoz, Princeton,
NJ), and rocuronium (50 mg; Organon Canada Ltd, Toronto, Ontario, Can-
ada) were administered intravenously. Under aseptic conditions, a thoracot-
omy was performed in the fifth left intercostal space. An aortotomy was
made, and the donor patch was sutured in place. An intra-aortic shunt
was used to minimize the risk of paralysis. Recipient animals were killed
by means of exsanguination, and the patches were explanted 4 weeks
(decellularized, n ¼ 6; control, n ¼ 4) or 6 months (decellularized,
n¼ 5; control, n¼ 8) after implantation to assess the early and late immune
response.
Immunohistochemistry
Explanted grafts were fixed and embedded in paraffin and then sectioned
(5 mm) and stained with hematoxylin and eosin and Movat’s pentachrome.
Other sections of the explanted grafts were stained for interstitial cells
(mouse anti-vimentin, 1:50; Dako Cytomation, Mississauga, Canada), en-
dothelial cells (anti-CD31 [MCA1812], 1:50, Serotec, Kidlington, United
Kingdom, and anti-von Willebrand factor [AB7356], 1:100, Chemicon In-
ternational, Temecula, Calif), B cells, (murine anti-CD79acy [M7051],
1:200, Dako), and transforming growth factor b (TGFB; anti-human
TGFB [MCA797], 1:100, Serotec). Suitable antibodies against ovine T cellsThe Journal of Thoracic and Carwere not available. Positive reactions were detected by using standard stain-
ing techniques with biotinylated secondary antibodies, peroxidase avidin–
biotin complex, and diaminobenzidine as a substrate for the enzyme. Slides
were examined with an Axioscope II equipped with an AxioCamMRc cam-
era and AxioVision 3.1 software (Carl Zeiss, Go¨ttingen, Germany).
Electron Microscopy
Sections of explanted patches were prefixed in 2.5% glutaraldehyde in
Millonig’s buffer (pH 7.2), washed in the same buffer, and placed in 1%
OsO4. After washing in distilled water, samples were dehydrated in ethanol.
Samples were dried in a CO2 critical-point dryer (Seevac, Inc, Pittsburgh,
Pa), mounted on aluminum stubs, and sputter coated with gold (Edwards
Sputter Coater, S150B). Digital micrographs of samples were taken with
a Hitachi Scanning Electron Microscope S2500 (Hitachi, Tokyo, Japan),
as previously described.17
Determination of Humoral Response
Sheep anti-sheep IgG antibodies in recipient blood serumwere measured
by means of flow cytometry, as previously described.18 Briefly, donor sple-
nocytes were isolated and frozen at a concentration of 2.53 107 mL in 10%
Me2SO and fetal bovine serum at86C. Serum was collected from the
blood of recipient animals at the time of implantation, weekly for 4 weeks,
and then monthly until the end of the experimental period and kept frozen at
86C. Splenocytes were thawed, washed in fluorescence-activated cell
sorting (FACS) buffer (phosphate-buffered saline and 1% fetal bovine
serum; Sigma, Oakville, Canada), resuspended (2.5 million cells/mL) in
50 mL of recipient serum (1:8 dilution in FACS buffer), and incubated at
37C in a humidified atmosphere of 5% CO2 for 1 hour. Splenocytes
were then washed and incubated with 50 mL of fluorescein isothiocyante–
conjugated AffiniPure rabbit anti-sheep IgG Fc fragment–specific antibody
(313-095-046, 1:200 dilution in FACS buffer; Jackson ImmunoResearch
Laboratories, Inc, West Grove, Pa) in the dark for 30 minutes at 4C. The
percentage of cells bound to antibody was detected from single-parameter
fluorescence histograms on a flow cytometer after gating on viable spleno-
cytes with Cellquest software for analysis (FACSCalibur; BD Biosciences,
Ontario, Canada). Controls for this experiment include sera taken at base-
line, unstained donor splenocytes, and donor splenocytes with secondary
antibody without recipient serum.
Calcification
Calcification is a common mode of allograft vascular conduit failure in
the clinical setting. Therefore calcium concentrations in the explanted sam-
ples were determined according to the methods described by Sarkar and
Chauhan19 and Lowry and colleagues20 and presented as micrograms per
milligram of protein.
RNA Isolation and Reverse Transcription–
Polymerase Chain Reaction
Samples of explanted patches taken away from the suture line were
crushed in liquid nitrogen and dissolved in 1 mL of Trizol reagent (Invitro-
gen, Carlsbad, Calif), and RNA was extracted. cDNA was constructed from
1 mg of total RNA by usingMultiScribe Reverse Transcriptase (Applied Bi-
osystems, Foster City, Calif), according to the manufacture’s protocol, and
1 mL of cDNA was amplified with AmpliTaq Gold (Applied Biosystems).
The polymerase chain reaction conditions were as follows: cDNA was de-
natured at 95C for 9 minutes, followed by amplification for 40 cycles at
95C for 30 seconds and annealing at 60C for 30 seconds, with a final ex-
tension of 72C for 12 minutes using primer pairs that span at least 1 intron
(Table 1). Polymerase chain reaction products were separated on an ethid-
ium bromide (Sigma)–stained agarose gel (1.5%), and images were cap-
tured with Alpha Digidoc software (PerkinElmer, Waltham, Mass). Bands
of the expected size were ligated in the pCR5-TOPO vector (TOPO TA
Cloning Kit for Sequencing, Invitrogen), sequenced (University of Albertadiovascular Surgery c Volume 141, Number 4 1057
TABLE 1. Primers used for PCR amplification
Gene Size (bp) Strand Sequence 50-30 GenBank ID
IL-2 214 F ATG CCC AAG GTT
AAC GCT AC
AF287479
R CAG CCT TTA CTG
TCG CAT CA
IL-4 206 F GTA CCA GCC ACT
TCG TCC AT
NM_001009313
R GCA CAT GTG GCT
CCT GTA GA
IL-10 201 F TGT TGA CCC AGT
CTC TGC TG
NM_001009327
R AGG GCA GAA AAC
GAT GAC AG
IFNG 236 F TAA GGG TGG GCC
TCT TTT CT
NM_001009803
R CAT CCA CCG GAA
TTT GAA TC
TNFA 335 F GGC TCT CCT GTC
TCC CGT
NM_001024860
R ATT GAT GGC TTT
GCG CTG
TGFB1 157 F CAC GTG GAG CTG
TAC CAG AA
NM_001009400
R GGC GAA AGC CTT
CTA TTT CC
GAPDH 310 F AAT CCC ATC ACC
ATC TTC CA
NM_008084
R GGC AGT GAT GGC
ATG GAC TG
IL, Interleukin; F, forward; R, reverse; IFN, interferon; TNF, tumor necrosis
factor; TGF, transforming growth factor; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
FIGURE 1. Gross pathology of decellularized patch implanted for
6 months at the time of explantation in situ (A) and immediately after
explantation (B).
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SDNA Core Laboratory), and compared with known GenBank sequences.
The positive control consisted of sheep spleen cDNA, and the negative con-
trol, which consisted of water in place of experimental cDNA and
glyceraldehyde-3-phosphate dehydrogenase (housekeeping gene), ensured
cDNA integrity.
Statistical Analysis
Continuous data were expressed as the mean  standard error of the
mean.Means of multiple groups were compared bymeans of 1-way analysis
of variance with Scheffe post hoc analysis to compare individual groups by
using SPSS 13.0 software (SPSS, Inc, Chicago, Ill).RESULTS
Clinical Results
A single animal receiving a decellularized patch died 61
days after implantation. At autopsy, the patch had dehisced
in the setting of empyema and a large abscess surrounding
the aorta at the surgical site. No other animals had significant
morbidities or mortality. On explantation, all decellularized
patches appeared to be well healed by 4 weeks without evi-
dence of aneurysmal dilation or major tissue failure on gross
examination (Figure 1).1058 The Journal of Thoracic and Cardiovascular SurHistology and Immunohistochemistry
Histologic assessment of the tissue before implantation
confirmed effective decellularization (Figure 2). No endo-
thelium was present, and only ghosts of cells were apprecia-
ble, whereas the internal and external elastic lamina were
preserved, as was the vaso vasorum. Four weeks after im-
plantation, control patches demonstrated findings consistent
with immune rejection (Figure 3). There was profound cel-
lular neointimal hyperplasia, and the media were edematous
and hypercellular with neovascularization. Hematoxylin and
eosin staining revealed lymphocytic infiltrates primarily
near the border of the external elastic lamina. The internal
and external elastic lamina were fragmented, as shown by
means ofMovat’s pentachrome staining, and smooth muscle
cell proliferation in the media was evident, as determined by
means of vimentin staining. There was increased vascularity
of the adventitia with thickened blood vessels, as shown
with CD31 and von Willebrand factor staining. None of
the cells in the infiltrate stained positive for B cells (CD79,gery c April 2011
FIGURE 2. Photomicrographs of representative sections of nondecellular-
ized and decellularized allogeneic ovine pulmonary artery patches at the
time of implantation (A and B) and 4 weeks after implantation (C–J).
Samples were fixed in formaldehyde, embedded in paraffin, and sectioned
Lehr et al Evolving Technology/Basic Science
The Journal of Thoracic and CarFigure 3). Similar findings were seen in control patches at
6 months (Figure 2).
Decellularized grafts demonstrated fewer features consis-
tent with immune rejection, although evidence of inflamma-
tion remained (Figure 2). Specifically, there was minimal
lymphocyte infiltrate in the decellularized graft at 4 weeks
and 6 months. The endothelial layer of the vaso vasorum
was much thinner compared with control patches. B cells
(CD79) were not identified in decellularized patches at
4 weeks or 6 months after implantation (Figure 2). TGFB
was strongly expressed, particularly at the medial–adventi-
tial junction at 4 weeks and 6 months in control patches
but only in occasional spindle cells in decellularized patches
at 4 weeks (data not shown).Scanning Electron Microscopy
Scanning electron microscopy of explanted grafts demon-
strated white blood cells on the surface of nondecellularized
grafts at 4 weeks. White blood cells were not seen on the en-
dothelial surface of decellularized grafts. The intimal surface
was fully re-endothelialized 4 weeks after implantation
(Figure 3).Humoral Response
Because decellularization attenuated the cellular immune
response, we examined the effect of decellularization on the
production of recipient anti-donor antibodies. In vivo pro-
duction of donor-specific antibodies was inhibited by decel-
lularization (Figure 4). When donor sheep cells were
incubated with recipient sheep sera, a trend toward reduced
binding of alloreactive murine IgG antibodies to donor sple-
nocytes was identified at 4 weeks (2.9 0.6 [decellularized]
vs 24.1  10.5 [nondecellularized], P ¼ .115, independent
samples t test, equal variance not assumed). Antibody pro-
duction peaked 3 to 4 months after surgical intervention,
at which point a significant difference was identified be-
tween groups (9.8  3.3 [decellularized] vs 57.8  13.7
[nondecellularized], P ¼ .010).at 5 mm. A and B represent grafts at the time of implantation (original mag-
nification 403). Solid arrows and open arrows indicate the external and in-
ternal lamina, respectively. Early and intense lymphocytic infiltrates are
profuse in nondecellularized patches but virtually absent in decellularized
grafts (C and D, original magnification 403). Both decellularized and non-
decellularized grafts show thickening of the intima and adventitia, as well as
disruption of the external elastic lamina with myofibroblastic proliferation
(Movat’s pentachrome stain, E and F, original magnification 403). Neovas-
cularization of the adventitia and media with thickened vessels was also de-
tected (von Willebrand factor positive, G and H; CD31þ, I and J; original
magnification 1003). B cells (CD79þ, K and L, original magnification
1003) were identified in the perivascular regions at the medial–adventitial
junction in nondecellularized control grafts at 6 months. CRYO, Cryopre-
served; CRYO & DECEL, cryopreserved and decellularized.
:
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FIGURE 3. Scanning electron microscopy of the endothelial surface of explanted nondecellularized and decellularized pulmonary artery patches at 4 weeks
after implantation. Both nondecellularized control (A and B) and decellularized (C) patches show re-endothelialization, but white blood cell infiltrate is iden-
tified only on nondecellularized control grafts. The bar indicates 10 mm in all electron micrographs.
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SCytokine Expression
mRNA transcripts for interferon g (IFNG, TH1 cytokine),
interleukin (IL) 10 (TH2 cytokine), andTGFB1 (regulatory cy-
tokine) were identified by means of reverse transcription–
polymerase chain reaction (RT–PCR) in all nondecellularized
grafts at 4 weeks. Fewer decellularized grafts expressed IL-10
(67%) and IFNG (67%) at 4 weeks, but TGFB1 was ex-
pressed in all grafts at 4 weeks (data not shown). mRNA tran-
scripts for IL-4were found in 2 of 4 nondecellularized grafts at
4 weeks but were not detected in any of the decellularized
grafts. Fifty percent of both decellularized and nondecellular-
ized grafts expressed tumor necrosis factor a. Seventy-five
percent of nondecellularized grafts expressed IL-2 at 4 weeks,
whereas IL-2 was expressed in only 50% of decellularized
grafts. Taken together, these results show that all cytokines
examined were detected in nondecellularized control allo-
grafts at 4 weeks but not at 6 months after transplantation,
indicating that there was complete cellular and humoral rejec-
tion of the graft at this time. In addition, decellularization
reduced both TH1 and TH2 cytokines.1060 The Journal of Thoracic and Cardiovascular SurCalcification
Calcification frequently causes allograft vascular tissue to
fail in the clinical setting. Therefore we sought to determine
the effect of decellularization on patch calcification by as-
sessing calcium levels in the grafts at 4 weeks and 6 months.
A trend toward a reduction in calcification was observed in
the decellularized group (7.6  4.3 vs 40.0  15.9 mg of
calcium/mg of protein, P ¼ .107).
DISCUSSION
Allograft valves and conduits have become a mainstay in
the surgical treatment of congenital heart defects but have
specific limitations leading to important clinical problems,
especially for the pediatric population. With current technol-
ogy, the problem of an imperfect donor allograft eliciting
a host immune response cannot be satisfactorily controlled.
Allogeneic valve grafts induce a host immune response that
might cause structural deterioration of the valve that is per-
haps the major obstacle to long-term graft viability. Immu-
nosuppressive agents might temper the host’s immunegery c April 2011
FIGURE 4. Flow cytometric determination of the humoral response of
sheep receiving allograft pulmonary artery patches. Recipient generation
of anti-donor IgG peaks at 2 months after implantation. Decellularization
of donor pulmonary artery patches eliminates the development of the recip-
ient humoral immune response. 2 Ab, Secondary antibody alone; FITC,
fluorescein isothiocyanate.
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plications related to immune suppression. Alternatively, the
allograft might be altered by eliminating alloantigens so that
the host immune response is not activated.
The current communication provides evidence that decel-
lularization of the graft in a large animal model can eliminate
both cellular and donor-specific humoral immune responses.
Without decellularization, infiltration of mononuclear im-
mune cells was evident 4 weeks after implantation; this
finding was persistent after 6 months and was confirmed
by electron microscopy. At 4 weeks, B cells (CD79þ) were
absent in the graft, but at 6 months, there was a population
of B cells among the infiltrating immune cells. Decellulari-
zation was effective at reducing the cellular infiltrate because
no immune cells were identified at either 4 weeks or 6
months after implantation.
There was a profound humoral immune response in ani-
mals receiving nondecellularized control patches, as evi-
denced by means of flow cytometry, that peaked between
3 and 4 months and then began to decrease, as expected,
when the primary response subsides. In contrast, animals re-
ceiving decellularized patches failed to generate any detect-
able anti-donor antibodies. The complete lack of antibody
levels above those seen in control animals, as well as the
lack of B cells in the patches, indicates a complete prevention
of the donor-specific humoral response against the grafts.
The mechanisms of cell signaling after implantation of al-
lografts or decellularized allografts have not been elucidated
in either small- or large-animal models. Our results provide
initial insights into 2 putative pathways that might be active.
By means of RT-PCR analysis, we demonstrated that decel-
lularization reduced the number of grafts expressing TH1
cytokines (IFNG) and TH2 cytokines (IL-10), but there wasThe Journal of Thoracic and Carno change in the number of grafts expressing TGFB1. These
results further suggest that rejection of the allograft vascular
patch is mediated by both cellular and humoral immune re-
sponses and that decellularization attenuates both of these re-
sponse mechanisms. In contrast, upregulation of TGFB1
might be a generalized response to the operation or represent
a non–antigen-dependent generalized response to vascular
injury. TGFB1 protein was not identified in the decellular-
ized patches; however, mRNA transcripts for this cytokine
were identified at 4 weeks. Although the literature reports di-
vergent roles for TGFB1, Schulick and associates21 demon-
strated that local upregulation of TGFB1 results in
cartilaginous metaplasia of the arterial wall and intimal
growth. This ongoing signal by TGFB1 might be the stimu-
lus for the profound endothelial hyperplasia seen in both
nondecellularized control patches and decellularized
patches. At 6 months, IFNG and IL-10 were no longer ex-
pressed in nondecellularized control patches, suggesting
that the graft was completely rejected at this time. Similarly,
at 6 months, TGFB1was not detected on tissue sections or in
RT-PCR analysis, further suggesting that the non–antigen-
dependent response had also subsided. Additional work is re-
quired to delineate further the cytokine pathways involved in
allograft rejection and in the response to the surgical proce-
dure. Future work might lead to adjunctive treatments that
could be beneficial in extending the durability of allograft
and tissue-engineered valve replacements. Although the ob-
served cellular response and in-graft cytokine production
might be representative of a general inflammatory reaction
against the implanted tissue, the humoral response confirms
anti-donor–specific reactivity.
Calcification is a common mechanism of allograft conduit
failure in the clinical setting. Other authors recently demon-
strated a reduction of valve calcification at 20 and 52 weeks
in a decellularized sheep model.22 We observed a trend to-
ward reduced calcification in decellularized grafts compared
with that seen in nondecellularized control patches that did
not reach statistical significance, perhaps because of the
small number of samples in each group. Evidence for struc-
tural changes in both control and decellularized patches after
implantation was also identified. The mechanism of these
changes is not evident based on this work, but it is unlikely
that these changes are an antigen-directed immune response
or related to the decellularization process given the lack of
antibody production and immune cell infiltrate. Moreover,
similar changes were identified in control and experimental
patches. It is possible that the cryopreservation method cre-
ated an injury that was not apparent based on histology but
manifests after implantation or that cryopreservation causes
injury, leading to a generalized tissue-directed host inflam-
matory response. It remains to be determined whether decel-
lularized valves are structurally weaker than standard
cryopreserved valves. Decellularized porcine valves im-
planted in the pediatric population elicited a profounddiovascular Surgery c Volume 141, Number 4 1061
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the valve wall and leaflets.23 The mechanisms resulting in
failure of these decellularized xenograft valves have not
been fully elucidated, but might be related to incomplete
decellularization, the decellularization process, or a xenoge-
neic immune response.24 We did not observe any structural
failures or aneurysm formation in either nondecellularized
control or decellularized patches.
Implanted decellularized patches showed myofibroblastic
repopulation of the matrix, although at this point, their po-
tential for contribution toward growth and repair is not clear.
The fact that the decellularized matrix can support infiltrat-
ing cells suggests that tissue-engineering strategies could
capitalize on this property. Indeed, decellularized heart ma-
trices have served as a scaffold for the regeneration of func-
tioning organs in vitro.25 Either the graft or the repopulating
cells could be manipulated to enhance repopulation and cell
function in the repopulated graft.
In conclusion, we provide additional evidence that allo-
graft vascular patch failure might be mediated by means of
allorejection. Osmotic lysis with detergent effectively decel-
lularized ovine pulmonary artery patches and attenuated
both the cellular and humoral allogeneic immune responses
in a large-animal model.
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